BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/10/2019 6:19:18 AM | Browse: 27 | Download: 36
Publication Name World Journal of Psychiatry
Manuscript ID 46491
Country of Manuscript Source United States
Received
2019-02-14 06:25
Peer-Review Started
To Make the First Decision
2019-03-08 01:11
Return for Revision
2019-03-08 01:48
Revised
2019-04-23 07:06
Second Decision
2019-05-10 09:48
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2019-05-11 15:09
Articles in Press
2019-05-11 15:09
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2019-06-05 23:54
Publish the Manuscript Online
2019-06-10 06:19
ISSN 2220-3206 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights re-served.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Specialty Psychiatry
Manuscript type Editorial
Article Title Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis
Manuscript Source Invited Manuscript
All Author List Rajesh R Tampi, Deena J Tampi, Juan J Young, Rakin A Hoq, Geetha Manikkara and Silpa Balachandran
ORCID
Author(s) ORCID Number
Rajesh R Tampi http://orcid.org/0000-0001-6754-6567
Deena J Tampi http://orcid.org/0000-0002-4349-7622
Juan J Young http://orcid.org/0000-0003-0058-0060
Rakin A Hoq http://orcid.org/0000-0002-3325-3042
Geetha Manikkara http://orcid.org/0000-0003-1958-3907
Silpa Balachandran http://orcid.org/0000-0002-1504-7878
Funding Agency and Grant Number
Correspondence To Rajesh R Tampi, MD, Chairman, Department of Psychiatry and Behavioral Sciences, Cleveland Clinic Akron General, Cleveland, NH, Ohio44106, United States. rajesh.tampi@yale.edu
Keywords Pimavanserin; Systematic review; Parkinson’s disease; Parkinson’s disease psychosis; Psychosis; Antipsychotic
Core Tip Pimavanserin is an atypical antipsychotic that was the first medication to be approved by the Food and Drug Administration for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). There are only two published tri-als that have evaluated the use of pimavanserin among individuals with PDP. Both studies are of good quality and found that pimavanserin improves psychotic symp-toms among individuals with PDP when compared to placebo. Additionally, pimavan-serin was fairly well tolerated in both studies and did not appear to cause significant sedation or worsen motor symptoms among individuals with PDP.
Publish Date 2019-06-10 06:19
Citation Tampi RR, Tampi DJ, Young JJ, Balachandran S, Hoq RA, Manikkara G. Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis. World J Psychiatr 2019; 9(3): 47-54
Url https://www.wjgnet.com/2220-3206/full/v9/i3/47.htm
DOI https://dx.doi.org/10.5498/wjp.v9.i3.47
Full Article (PDF) WJP-9-47.pdf
Full Article (Word) WJP-9-47.docx
Manuscript File 46491-Review.docx
Audio Core Tip 46491-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 46491-Conflict-of-interest statement.pdf
Copyright License Agreement 46491-Copyright license agreement.pdf
Scientific Misconduct Check 46491-Scientific misconduct check.pdf
Scientific Editor Work List 46491-Scientific editor work list.pdf